Preclinical Development of the Live, Single-Cycle, Next-Generation SARS-CoV-2 Vaccine (RVX-13)

• Unité de recherche: INNOSUISSE
• Numéro de projet: 52533.1 IP-LS
• Titre du projet anglais: Preclinical Development of the Live, Single-Cycle, Next-Generation SARS-CoV-2 Vaccine (RVX-13)

Description succincte (Allemand)

Preclinical Development of the Live, Single-Cycle, Next-Generation SARS-CoV-2 Vaccine (RVX-13)

Description succincte (Anglais)

Preclinical Development of the Live, Single-Cycle, Next-Generation SARS-CoV-2 Vaccine (RVX-13)

Résumé des résultats (Abstract) (Allemand)

RocketVax AG, a startup company from Basel, together with academic partners in Switzerland, will develop a next-generation vaccine against SARS-CoV-2. Based on a live, single-cycle virus, this vaccine will provide a broader and more durable protection, offering a superior and long-term solution.